Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06369675 · ClinicalTrials.gov registry record · Phase 1
Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design
A Phase 1 study, sponsored by Moberg Pharma AB.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT06369675 is a Phase 1 study that has completed, run by Moberg Pharma AB. The registered enrollment target is 45 participants.
The verdict
NCT06369675, a Phase 1 study, has completed, sponsored by Moberg Pharma AB.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
A 21-Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design To evaluate the irritation potential of MOB015B on normal skin. Single center, randomized, controlled, evaluator blinded, within-subject comparison study
Interventions
- DRUG MOB015B
- DRUG 0.9% Saline
- DRUG MOB015B vehicle
- DRUG 0.2% SLS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-10-19 |
| Est. Completion | 2017-11-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06369675
The ClinicalTrials.gov registry entry for NCT06369675 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Moberg Pharma AB, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which MOB015B is the first listed.
NCT06369675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06369675 about?
NCT06369675 is a clinical study titled "Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design". A 21-Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design To evaluate the irritation potential of MOB015B on normal skin. Single center, randomized, controlled, evaluator blinded, within-subject compa...
What is the current status of trial NCT06369675?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2017-10-19. Estimated completion is 2017-11-14.
What interventions are being tested in trial NCT06369675?
The interventions under investigation include: MOB015B (DRUG), 0.9% Saline (DRUG), MOB015B vehicle (DRUG), 0.2% SLS (DRUG).
Who is sponsoring clinical trial NCT06369675?
This trial is sponsored by Moberg Pharma AB, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.